CancerX Startup Accelerator

in partnership with

MassChallenge

CancerX is thrilled to announce the graduation of the 16 startup companies from our Accelerator program’s inaugural cohort!

The digital innovators in the inaugural class were selected from a strong pool of over 100 Startup applicants after sharing their ideas for digital innovation in clinical research, screening and diagnosis, treatment and management, clinical operations, and patient, caregiver, and survivor experience, aiming to reduce the burden of cancer for all people.

Over four months, the Startups attended two full-day workshops with leaders at Moffitt Cancer Center and Advocate Health and engaged in 16 curriculum sessions led by the Champions and mentors. Topics included business scaling, government innovation, frontline healthcare, and industry partnerships, which assisted the startups in growing their businesses in various areas.

By graduating from the Accelerator program, these startups have a roadmap to successfully scale their company, an opportunity to move forward with their sponsor, and a strong community supporting their development. Because of the collaboration, support, and incredible contributions between Startups, Champions, and Mentors in the Accelerator program, the inaugural class is expediting and scaling ideas to save lives and improve the experience of cancer patients and their caregivers.

The success of the CancerX Accelerator program is another milestone for CancerX in achieving our mission to unite a diverse and inclusive community of stakeholders and harness our collective superpowers to rapidly pioneer and equitably deploy innovative solutions that can prevent and cure cancer.

Xanthos

Startup Success Stories

Curiva provides a microneedles-mediated diagnostic patch, diaPatchTM, for the detection of early-onset cervical cancer, replacing invasive procedures such as the Pap smear and colposcopy.

Flip to see more.

By collaborating with Accelerator Champions, Curiva is accelerating the journey of getting diaPatchTM to patients enrolling in trials ahead of schedule. With the Champions' support, ranging from resources, strategic planning, and investor exposure, Curiva has made significant strides in getting the diaPatchTM MVP into a pilot study in the research-use-only setting, impacting over 300,000 women globally.

Navya is known for its patented AI/ML technologies, which have impacted over 100,000 cancer patients and over 300 tertiary cancer experts. Their AI-enabled clinical navigation simplifies expert treatment plans for patients.

Flip to see more.

The CancerX Accelerator program has provided Navya with the resources and support needed to scale the adoption of its AI capabilities among expert centers, leading to a pilot, amplifying its impact on a larger number of patients. The Accelerator was crucial in advancing Navya’s mission of scaling access to expertise, ultimately enhancing cancer care delivery and patient outcomes.

Cancer Insights provides an end-to-end oncology product suite that enables care teams to run collaborative and streamlined clinical workflows from referral to survivorship on an EMR-integrated and AI-enabled platform.

Flip to see more.

Participating in the CancerX Accelerator program has proven pivotal in testing and deploying Cancer Insight’s technology at the world’s most innovative cancer centers and co-creating the future of cancer care. Through the Accelerator's collaboration, Cancer Insights believes cancer-related mortality can be reduced to 50%, with cancer changing from a life-threatening disease to a manageable medical condition.

Accelerator Cohort 2024

Learn more about the 16 Accelerator Startups and more than 100 Mentors who worked together to test and validate new innovative solutions.

Startups
Mentors

CancerX is proud to recognize the generous contribution of our Platinum Champions and Gold Champions. Thank you for your support and investment in digital innovations that aim to reduce the burden of cancer for all people.

Platinum Champions

Debiopharm Innovation Fund logo
MassChallenge
Reveal Prism

Gold Champions

AstraZeneca
Atrium-Health-UPDATED.png
AWS
DellTech_Logo_Prm_Blue_Gry_rgb
Intel
Oncology Ventures
UC Davis Health

Sign up to be the first to hear about details for Cohort 2025

After the incredible success of the first Cohort, we are thrilled to offer organizations the chance to be involved in our next cohort! Submissions for Cohort 2025 will open this fall, and if you want to join the CancerX Accelerator as a Startup, Champion, or Mentor, sign up for updates and be among the first to learn more about Cohort 2025.

Name(Required)
I’m interested in joining Cohort 2025 as a:

More About CancerX Accelerator

CancerX Accelerator is the first-ever innovation accelerator to focus at the intersection of digital innovation and cancer. It uniquely brings together a community of champions, innovators, and users of digital health in oncology to generate and scale ideas that have the potential to solve unmet needs in clinical delivery for cancer patients and providers.

Every fall, submissions open for the next Accelerator cohort, and a panel of esteemed CancerX Champions and judges conduct several rounds of judging during winter to select the startup finalists.